94233-4 |
FECH gene full mutation analysis |
Find |
Bld/Tiss |
Pt |
Doc |
Sequencing |
|
ACTIVE |
FECH gene full mutation analysis in Blood or Tissue by Sequencing |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MOLPATH |
|
94233-4 |
|
Sequencing |
|
|
Both |
|
|
|
0 |
FECH gene Full Mut Anl Bld/T Seq |
|
|
|
|
|
Blood; Document; EPP; FCE; ferrochelatase; Finding; Findings; full gene sequencing; Full Mut Anl; Genetics; Heredity; Heritable; high-throughput sequencing; HTS; Inherited; Molecular pathology; MOLPATH; Mut; Mutations; Next generation sequencing; NGS; Point in time; Random; sequencing of entire coding region; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.68 |
2.68 |
|
|
|
|
|
|
|
|
|
|
|
0 |
94234-2 |
F8 gene full mutation analysis |
Find |
Bld/Tiss |
Pt |
Doc |
Sequencing |
|
ACTIVE |
F8 gene full mutation analysis in Blood or Tissue by Sequencing |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MOLPATH |
|
94234-2 |
|
Sequencing |
|
|
Both |
|
|
|
0 |
F8 gene Full Mut Anl Bld/T Seq |
|
|
|
|
|
AHF; Blood; Classic hemophilia; Coagulation Factor VIII gene; coagulation factor VIII, procoagulant component; Document; DXS1253E; F8B; F8C; Factor 8; Finding; Findings; full gene sequencing; Full Mut Anl; FVIII; FVIII gene; Genetics; Haemophilia; HEMA; Hemophilia A; Heredity; Heritable; high-throughput sequencing; HTS; Inherited; Molecular pathology; MOLPATH; Mut; Mutations; Next generation sequencing; NGS; Point in time; Procoagulant component; Random; sequencing of entire coding region; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.68 |
2.68 |
|
|
|
|
|
|
|
|
|
|
|
0 |
94235-9 |
F7 gene full mutation analysis |
Find |
Bld/Tiss |
Pt |
Doc |
Sequencing |
|
ACTIVE |
F7 gene full mutation analysis in Blood or Tissue by Sequencing |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MOLPATH |
|
94235-9 |
|
Sequencing |
|
|
Both |
|
|
|
0 |
F7 gene Full Mut Anl Bld/T Seq |
|
|
|
|
|
Blood; CF gene; coagulation factor VII (serum prothrombin conversion accelerator); Coagulation factor VII gene; Document; Factor 7; Factor VII; Finding; Findings; full gene sequencing; Full Mut Anl; Genetics; Heredity; Heritable; high-throughput sequencing; HTS; Inherited; Molecular pathology; MOLPATH; Mut; Mutations; Next generation sequencing; NGS; Point in time; Random; sequencing of entire coding region; Serum prothrombin conversion accelerator; SPCA; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.68 |
2.68 |
|
|
|
|
|
|
|
|
|
|
|
0 |
94236-7 |
F5 gene full mutation analysis |
Find |
Bld/Tiss |
Pt |
Doc |
Sequencing |
|
ACTIVE |
F5 gene full mutation analysis in Blood or Tissue by Sequencing |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MOLPATH |
|
94236-7 |
|
Sequencing |
|
|
Both |
|
|
|
0 |
F5 gene Full Mut Anl Bld/T Seq |
|
|
|
|
|
Activated protein C cofactor; APC; Blood; Coagulation Factor V - Leiden gene; coagulation factor V (proaccelerin, labile factor); Document; Finding; Findings; full gene sequencing; Full Mut Anl; FVL; Genetics; Heredity; Heritable; high-throughput sequencing; HTS; Inherited; Labile factor; Molecular pathology; MOLPATH; Mut; Mutations; Next generation sequencing; NGS; PCCF; Point in time; Proaccelerin gene; Random; RPRGL1; sequencing of entire coding region; THPH2; Thrombophilia; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.68 |
2.68 |
|
|
|
|
|
|
|
|
|
|
|
0 |
94237-5 |
F2 gene full mutation analysis |
Find |
Bld/Tiss |
Pt |
Doc |
Sequencing |
|
ACTIVE |
F2 gene full mutation analysis in Blood or Tissue by Sequencing |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MOLPATH |
|
94237-5 |
|
Sequencing |
|
|
Both |
|
|
|
0 |
F2 gene Full Mut Anl Bld/T Seq |
|
|
|
|
|
Blood; Coagulation Factor 2 gene; coagulation factor II (thrombin); Coagulation Factor II gene; Document; Finding; Findings; full gene sequencing; Full Mut Anl; Genetics; Heredity; Heritable; high-throughput sequencing; HTS; Inherited; Molecular pathology; MOLPATH; Mut; Mutations; Next generation sequencing; NGS; Point in time; Prothrombin gene; Prothrombin precursor; PT; Random; RPRGL2; sequencing of entire coding region; THPH1; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.68 |
2.68 |
|
|
|
|
|
|
|
|
|
|
|
0 |
94238-3 |
F12 gene full mutation analysis |
Find |
Bld/Tiss |
Pt |
Doc |
Sequencing |
|
ACTIVE |
F12 gene full mutation analysis in Blood or Tissue by Sequencing |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MOLPATH |
|
94238-3 |
|
Sequencing |
|
|
Both |
|
|
|
0 |
F12 gene Full Mut Anl Bld/T Seq |
|
|
|
|
|
beta-factor XIIa part 1; Blood; coagulation factor XII; coagulation factor XII (Hageman factor); coagulation factor XIIa heavy chain; coagulation factor XIIa light chain; Document; EC 3.4.21.38; Finding; Findings; full gene sequencing; Full Mut Anl; Genetics; HAE3; HAEX; HAF; Hageman factor; Heredity; Heritable; high-throughput sequencing; HTS; Inherited; Molecular pathology; MOLPATH; Mut; Mutations; Next generation sequencing; NGS; Point in time; Random; sequencing of entire coding region; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.68 |
2.68 |
|
|
|
|
|
|
|
|
|
|
|
0 |
94239-1 |
F11 gene full mutation analysis |
Find |
Bld/Tiss |
Pt |
Doc |
Sequencing |
|
ACTIVE |
F11 gene full mutation analysis in Blood or Tissue by Sequencing |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MOLPATH |
|
94239-1 |
|
Sequencing |
|
|
Both |
|
|
|
0 |
F11 Full Mut Anl Bld/T Seq |
|
|
|
|
|
Blood; Coagulation factor XI; Document; Finding; Findings; full gene sequencing; Full Mut Anl; FXI; Genetics; Heredity; Heritable; high-throughput sequencing; HTS; Inherited; Lemierre syndrome; Molecular pathology; MOLPATH; Mut; Mutations; Next generation sequencing; NGS; Plasma thromboplastin antecedent; Point in time; PTA; Random; sequencing of entire coding region; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.68 |
2.68 |
|
|
|
|
|
|
|
|
|
|
|
0 |
9424-3 |
Intercellular substance Ab |
Titr |
Ser |
Pt |
SemiQn |
|
|
ACTIVE |
Intercellular substance Ab [Titer] in Serum |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
SERO |
|
9424-3 |
|
|
|
|
Both |
|
|
|
0 |
ICS Ab Titr Ser |
|
|
|
Y |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Cell surface; Dilution factor; Dilution Factor (Titer); ICS; Intercellular structure; Paraneoplastic pemphigus; Pemphigus; Point in time; Random; Serology; Serum; SmQn; SR; Subs; Titer; Titered; Titre; Ttr |
2.75 |
1.0i |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
94240-9 |
CDH1 gene deletion+duplication & full mutation analysis |
Find |
Bld/Tiss |
Pt |
Doc |
Molgen |
|
ACTIVE |
CDH1 gene deletion+duplication and full mutation analysis in Blood or Tissue by Molecular genetics method |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MOLPATH |
|
94240-9 |
|
Molgen |
|
|
Both |
|
|
|
0 |
CDH1 gene Del+Dup + Full Mut Anl Bld/T |
|
|
|
|
|
Amplification; Arc-1; Blood; Cadherin 1; cadherin 1, type 1, E-cadherin (epithelial); Calcium dependent adhesion protein epithelial; CD324; CDHE; Del; Del+Dup; Del+Dup + Full Mut Anl; Deletions; Document; Dp; ECAD; E-cadherin gene; Finding; Findings; full gene sequencing; Full Mut Anl; Genetics; Heredity; Heritable; Inherited; LCAM; Molecular genetics; Molecular pathology; MOLPATH; Mut; Mutations; PCR; Point in time; Random; sequencing of entire coding region; Tissue; Tissue, unspecified; UVO; Uvomorulin; WB; Whole blood; Whole blood or Tissue |
2.68 |
2.68 |
|
|
|
|
|
|
|
|
|
|
|
0 |
94241-7 |
BTK gene full mutation analysis |
Find |
Bld/Tiss |
Pt |
Doc |
Sequencing |
|
ACTIVE |
BTK gene full mutation analysis in Blood or Tissue by Sequencing |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MOLPATH |
|
94241-7 |
|
Sequencing |
|
|
Both |
|
|
|
0 |
BTK gene Full Mut Anl Bld/T Seq |
|
|
|
|
|
Agammaglobulinaemia tyrosine kinase gene; AGMX1; AT; ATK; B cell progenitor kinase gene; Blood; BPK; Bruton agammaglobulinemia tyrosine kinase; Bruton agammaglobulinemia tyrosine kinase gene; Bruton's tyrosine kinase gene; Document; Finding; Findings; full gene sequencing; Full Mut Anl; Genetics; Heredity; Heritable; high-throughput sequencing; HTS; IMD1; Inherited; Molecular pathology; MOLPATH; Mut; Mutations; Next generation sequencing; NGS; Point in time; PSCTK1; Random; sequencing of entire coding region; Tissue; Tissue, unspecified; Tyrosine-protein kinase gene; WB; Whole blood; Whole blood or Tissue; XLA |
2.68 |
2.68 |
|
|
|
|
|
|
|
|
|
|
|
0 |
94242-5 |
BTD gene full mutation analysis |
Find |
Bld/Tiss |
Pt |
Doc |
Sequencing |
|
ACTIVE |
BTD gene full mutation analysis in Blood or Tissue by Sequencing |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MOLPATH |
|
94242-5 |
|
Sequencing |
|
|
Both |
|
|
|
0 |
BTD gene Full Mut Anl Bld/T Seq |
|
|
|
|
|
biotinase; biotinidase; Blood; Document; Finding; Findings; full gene sequencing; Full Mut Anl; Genetics; Heredity; Heritable; high-throughput sequencing; HTS; Inherited; Molecular pathology; MOLPATH; Mut; Mutations; Next generation sequencing; NGS; Point in time; Random; sequencing of entire coding region; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.68 |
2.68 |
|
|
|
|
|
|
|
|
|
|
|
0 |
94243-3 |
Note |
Find |
{Setting} |
Pt |
Doc |
Healthcare navigator |
|
ACTIVE |
Healthcare navigator Note |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DOC.ONTOLOGY |
|
94243-3 |
|
Healthcare navigator |
|
|
Observation |
|
|
|
0 |
Navigator Note |
|
|
|
|
|
DOC.ONT; Document; Encounter; Evaluation and management; Evaluation and management note; Finding; Findings; notes; Point in time; Random; Visit note |
2.68 |
2.68 |
|
|
|
|
|
|
|
|
|
|
|
0 |
94244-1 |
Plan of care note |
Find |
{Setting} |
Pt |
Doc |
Wound, ostomy, and continence care |
|
ACTIVE |
Wound, Ostomy, and Continence Care Plan of care note |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DOC.ONTOLOGY |
|
94244-1 |
|
Wound, ostomy, and continence care |
|
|
Observation |
|
|
|
0 |
WOC Plan of care note |
|
|
|
|
|
Care plan; Continuity assessment record and evaluation; DOC.ONT; Document; Encounter; Evaluation and management; Evaluation and management note; Finding; Findings; notes; Point in time; Random; Treatment plan; Visit note; WOC |
2.68 |
2.68 |
|
|
|
|
|
|
|
|
|
|
|
0 |
94245-8 |
Progress note |
Find |
{Setting} |
Pt |
Doc |
Wound, ostomy, and continence care |
|
ACTIVE |
Wound, Ostomy, and Continence Care Progress note |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DOC.ONTOLOGY |
|
94245-8 |
|
Wound, ostomy, and continence care |
|
|
Observation |
|
|
|
0 |
WOC Prog note |
|
|
|
|
|
Continuity assessment record and evaluation; DOC.ONT; Document; Encounter; Evaluation and management; Evaluation and management note; Finding; Findings; notes; Point in time; Prog note; Random; subsequent evaluation; subsequent visit evaluation; Visit note; WOC |
2.73 |
2.68 |
|
|
|
|
|
|
|
|
|
|
|
0 |
94246-6 |
Note |
Find |
Telephone encounter |
Pt |
Doc |
Wound, ostomy, and continence care |
|
ACTIVE |
Wound, Ostomy, and Continence Care Telephone encounter Note |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DOC.ONTOLOGY |
|
94246-6 |
|
Wound, ostomy, and continence care |
|
|
Observation |
|
|
|
0 |
WOC Phone Note |
|
|
|
|
|
Continuity assessment record and evaluation; DOC.ONT; Document; Encounter; Evaluation and management; Evaluation and management note; Finding; Findings; notes; Point in time; Random; Visit note; WOC |
2.68 |
2.68 |
|
|
|
|
|
|
|
|
|
|
|
0 |
94247-4 |
Borrelia burgdorferi oppA2 gene |
PrThr |
Bld |
Pt |
Ord |
Non-probe.amp.tar |
|
ACTIVE |
Borrelia burgdorferi oppA2 gene [Presence] in Blood by NAA with non-probe detection |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
94247-4 |
|
Non-probe.amp.tar |
|
|
Both |
|
|
|
0 |
B burgdorferi oppA2 Bld Ql NAA+non-probe |
|
|
|
|
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; B burg; B burgdor; B burgdorferi; B burgdorferi oppA2; Bb; Blood; Burgdorf; DNA NUCLEIC ACID PROBE; DNA probe; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Lyme; Lyme disease; Lymes; Microbiology; NAA+non-probe; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Ordinal; PCR; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; Screen; SDA; Strand Displacement Amplification; TMA; Transcription mediated amplification; WB; Whole blood |
2.68 |
2.68 |
|
|
|
|
|
|
|
|
|
|
|
0 |
94248-2 |
Borrelia mayonii oppA2 gene |
PrThr |
Bld |
Pt |
Ord |
Non-probe.amp.tar |
|
ACTIVE |
Borrelia mayonii oppA2 gene [Presence] in Blood by NAA with non-probe detection |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
94248-2 |
|
Non-probe.amp.tar |
|
|
Both |
|
|
|
0 |
B mayonii oppA2 Bld Ql NAA+non-probe |
|
|
|
|
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; B mayonii; B mayonii oppA2; Blood; DNA NUCLEIC ACID PROBE; DNA probe; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Lyme; Microbiology; NAA+non-probe; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Ordinal; PCR; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; Screen; SDA; Strand Displacement Amplification; Tick-Borne Disease; TMA; Transcription mediated amplification; WB; Whole blood |
2.68 |
2.68 |
|
|
|
|
|
|
|
|
|
|
|
0 |
94249-0 |
Borrelia garinii+afzelii oppA2 gene |
PrThr |
Bld |
Pt |
Ord |
Non-probe.amp.tar |
|
ACTIVE |
Borrelia garinii+afzelii oppA2 gene [Presence] in Blood by NAA with non-probe detection |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
94249-0 |
|
Non-probe.amp.tar |
|
|
Both |
|
|
|
0 |
B gar+afz oppA2 Bld Ql NAA+non-probe |
|
|
|
|
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; B gar+afz oppA2; B garinii; Blood; DNA NUCLEIC ACID PROBE; DNA probe; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; NAA+non-probe; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Ordinal; PCR; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; Screen; SDA; Strand Displacement Amplification; TMA; Transcription mediated amplification; WB; Whole blood |
2.68 |
2.68 |
|
|
|
|
|
|
|
|
|
|
|
0 |
9425-0 |
Acetone |
MCnc |
Bld |
Pt |
Qn |
|
|
ACTIVE |
Acetone [Mass/volume] in Blood |
|
MIN |
DefinitionDescription |
|
|
mg/dL |
|
|
|
|
|
|
DRUG/TOX |
|
9425-0 |
|
|
|
|
Both |
|
|
|
0 |
Acetone Bld-mCnc |
|
|
|
Y |
|
2-propanone; Blood; DRUG/TOXICOLOGY; Drugs; Ketone bodies; Level; Mass concentration; Me2CO; Point in time; QNT; Quan; Quant; Quantitative; Random; WB; Whole blood |
2.73 |
1.0i |
|
|
|
|
|
|
|
mg/dL |
|
|
|
0 |
94250-8 |
Borrelia burgdorferi oppA2 gene |
PrThr |
XXX |
Pt |
Ord |
Non-probe.amp.tar |
|
ACTIVE |
Borrelia burgdorferi oppA2 gene [Presence] in Specimen by NAA with non-probe detection |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
94250-8 |
|
Non-probe.amp.tar |
|
|
Observation |
|
|
|
0 |
B burgdorferi oppA2 Spec Ql NAA+non-prb |
|
|
|
|
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; B burg; B burgdor; B burgdorferi; B burgdorferi oppA2; Bb; Burgdorf; DNA NUCLEIC ACID PROBE; DNA probe; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Lyme; Lyme disease; Lymes; Microbiology; Misc; Miscellaneous; NAA+non-probe; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Ordinal; Other; PCR; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; Screen; SDA; Spec; Strand Displacement Amplification; TMA; To be specified in another part of the message; Transcription mediated amplification; Unspecified |
2.69 |
2.68 |
|
|
|
|
|
|
|
|
|
|
|
0 |
94251-6 |
Borrelia mayonii oppA2 gene |
PrThr |
XXX |
Pt |
Ord |
Non-probe.amp.tar |
|
ACTIVE |
Borrelia mayonii oppA2 gene [Presence] in Specimen by NAA with non-probe detection |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
94251-6 |
|
Non-probe.amp.tar |
|
|
Both |
|
|
|
0 |
B mayonii oppA2 Spec Ql NAA+non-probe |
|
|
|
|
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; B mayonii; B mayonii oppA2; DNA NUCLEIC ACID PROBE; DNA probe; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Lyme; Microbiology; Misc; Miscellaneous; NAA+non-probe; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Ordinal; Other; PCR; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; Screen; SDA; Spec; Strand Displacement Amplification; Tick-Borne Disease; TMA; To be specified in another part of the message; Transcription mediated amplification; Unspecified |
2.69 |
2.68 |
|
|
|
|
|
|
|
|
|
|
|
0 |
94252-4 |
Borrelia garinii+afzelii oppA2 gene |
PrThr |
XXX |
Pt |
Ord |
Non-probe.amp.tar |
|
ACTIVE |
Borrelia garinii+afzelii oppA2 gene [Presence] in Specimen by NAA with non-probe detection |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
94252-4 |
|
Non-probe.amp.tar |
|
|
Both |
|
|
|
0 |
B gar+afz oppA2 Spec Ql NAA+non-probe |
|
|
|
|
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; B gar+afz oppA2; B garinii; DNA NUCLEIC ACID PROBE; DNA probe; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; Misc; Miscellaneous; NAA+non-probe; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Ordinal; Other; PCR; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; Screen; SDA; Spec; Strand Displacement Amplification; TMA; To be specified in another part of the message; Transcription mediated amplification; Unspecified |
2.69 |
2.68 |
|
|
|
|
|
|
|
|
|
|
|
0 |
94253-2 |
Borrelia sp panel |
- |
XXX |
Pt |
- |
Non-probe.amp.tar |
|
ACTIVE |
Borrelia sp panel - Specimen by NAA with non-probe detection |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.MICRO |
|
94253-2 |
|
Non-probe.amp.tar |
|
|
Order |
|
|
|
0 |
B sp panel Spec NAA+non-probe |
|
|
|
|
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; B sp panel; DNA NUCLEIC ACID PROBE; DNA probe; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Lyme; Lyme disease; Microbiology; Misc; Miscellaneous; NAA+non-probe; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Other; Pan; PANEL.MICROBIOLOGY; Panl; PCR; Pnl; Point in time; Polymerase chain reaction; Probe amp; Probe with ampification; Probe with target amplification; QBR; Random; Relapsing fever; SDA; Spec; species; spp; Strand Displacement Amplification; TMA; To be specified in another part of the message; Transcription mediated amplification; Unspecified |
2.69 |
2.68 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
94254-0 |
CYP1A2 gene product metabolic activity interpretation |
Imp |
Bld/Tiss |
Pt |
Ord |
Molgen |
|
ACTIVE |
CYP1A2 gene product metabolic activity interpretation in Blood or Tissue Qualitative by Molecular genetics method |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MOLPATH.PHARMG |
|
94254-0 |
|
Molgen |
|
|
Observation |
|
|
|
0 |
CYP1A2 gene prod met act Bld/T-Imp |
|
|
|
|
|
Activ; Actvty; Blood; CP12; CYP1A2 gene prod met act; cytochrome P450, family 1, subfamily A, polypeptide 2; Drug metabolism; Gene prod met act imp; Genetics; Heredity; Heritable; Impression; Impression/interpretation of study; Impressions; Inherited; Interp; Interpret; Interpretation; Interpt; Intrp; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.PHARMG; Movements; Ordinal; P3-450; P450(PA); PCR; Phenotype; Point in time; QL; Qual; Qualitative; Random; Screen; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.68 |
2.68 |
|
|
|
|
|
|
|
|
|
|
|
0 |
94255-7 |
Calcium |
MCnc |
Sweat |
Pt |
Qn |
|
|
ACTIVE |
Calcium [Mass/volume] in Sweat |
|
ADD |
DefinitionDescription |
|
|
mg/dl |
|
|
|
|
|
|
CHEM |
|
94255-7 |
|
|
|
|
Both |
|
|
|
0 |
Calcium Sweat-mCnc |
|
|
|
|
|
Ca; Cal; Chemistry; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; SWT |
2.68 |
2.68 |
|
|
|
|
|
|
|
mg/dL |
|
|
|
0 |